Bartomeu Massuti, Associate Professor at Miguel Hernandez University of Elche, shared a post on X:
“Optó-TROP 01 Lung study: Sacitumumab-Tirumoten plus Immunity-Checkpoint-Inhibitor approach in pretreated NSCLC at ASCO24: interesting results but development continues with Pembrolizumab.”
Source: Bartomeu Massuti/X
